In a randomized trial conducted by the Italian Gastric Cancer study group, D2 lymphadenectomy resulted in a marginally significant improvement in the disease-specific survival of patients with pathologic T2–4 and LN metastasis (hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.36–1.06; P=0.078) [ 27 ].
1
—
—